Shots: NanoString to receive $40M in cash & $10M in Veracyte’s stock along with $10M as milestones. Veracyte to get an exclusive global right to develop and commercialize diagnostic tests […]readmore
Tags : Agreement
Shots: GE Healthcare will install 200+ new equipment including 60 new MRIs, 50 ultrasound devices, 40 CT scanners, and 30 X-rays machines in the next 3 yrs. in Affidea’s network […]readmore
Shots: GTS and Kishi Kasei will jointly develop biosimilar of Aflibercept and will form a manufacturing process for the drug substance utilizing high-yield protein-producing cell lines, which were jointly developed […]readmore
Shots: Neurocrine to receive exclusive license to Xenon’s XEN901 including two preclinical candidates including selective Nav1.6 inhibitors and dual Nav1.2/1.6 inhibitors involving activities to discover, develop and identify additional novel […]readmore
Shots: GI to receive up front, milestones, and royalties on sales in China, including mainland China, Hong Kong, Macau, and Taiwan while Simcere will be responsible for all clinical development, […]readmore
Shots: Skyhawk to receive $80M up front, milestones, and royalties on sales. Celgene to get exclusive WW option to license IPR for the number of Skyhawk’s candidates targeting multiple autoimmune […]readmore
Shots: Promega and Merck collaborated to develop Promega’s microsatellite instability (MSI) technology as an on-label solid tumor CDx for use with Merck’s Keytruda (pembrolizumab) Promega’s Microsatellite Instability technology measures the […]readmore
Shots: Vyriad to receive upfront, development and commercial milestone payments based on certain achievements and royalties on sales of products. Regeneron to get an exclusive option to license Vyriad’s Voyager-V1 […]readmore
Shots: Takeda to get rights to develop and commercialize up to four programs including a CD19-targeted CAR NK-cell therapy and a B-cell maturation antigen (BCMA)-targeted CAR NK-cell therapy and will […]readmore
Shots: Seattle to receive upfront plus progress-dependent milestones of up to $160M and royalties on any product sales, retaining rights for candidates in Americas (the US, Canada, and Latin American […]readmore